Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘ASCO 2018 Preview’

One thing that often comes up is why don’t all inflamed tumours respond to immune checkpoint blockade or immunotherapy – it is that PD-L1 is a weak biomarker of response or are there factors that can explain the phenomenon?

ASCO 2011 #BlisterWalk

The ASCO #blisterwalk

Some new research now sheds some light on the issue.

This seemed to be a great opportunity to explore several topics around this theme and look at what the data from AACR and ASCO are potentially telling us.

Obviously we need to see the presentations in Chicago to be sure, but the good thing is that there are some good hints of where to start and what to think about going forward since they could have an impact on clinical trial design.

With a lot of observers focused on some disappointing results from, for example, Incyte’s epacadostat (IDO) and Jounce’s ICOS antibody, are there things we can do to improve the chances of success?

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

In the frantic rush to the clinic with various IO-IO combinations, many people seem to have forgotten that these have an increased risk of failure than say, combining one IO molecule with chemotherapy.

This risk can take the form of increased toxicities, as well as lack of efficacy, especially if you are giving an unknown therapy instead of one that is known to be effective in controlling the tumour.

We look at a tale of two cities in lung cancer; there are some interesting lessons to be learned here…

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

It’s a Bank Holiday weekend on both sides of the pond, which is always a good excuse for some shorter snippets as everyone will be enjoying the break outside, weather permitting!

In our latest Preview series, we address some pertinent questions that have come in from BSB readers on several topics in between AACR and ASCO, including tumour mutation burden (TMB), the PACIFIC trial, monalizumab, renal cell carcinoma (RCC) and castrate resistant prostate cancer (CRPC).

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Chicago Loop Train

In this latest ASCO 2018 Preview, we take a look at tissue and blood based biomarkers to see what we can learn and whether they look useful or not for predicting which patients should receive a therapy or not.

There’s quite a lot we can learn from the latest data from the initial abstracts ahead of the meeting in order to be better prepared about what to expect in Chicago.

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Downtown Chicago

In our latest ASCO 2018 Preview series we take a look at some of the key highlights from urothelial and bladder cancers and look at how new developments in this space are progressing.

Historically in oncology, we see initial trials begin in advanced stage disease especially in the refractory metastatic setting and move up into earlier lines of therapy later as safety and efficacy become more established.

This situation has been very much the case in urothelial carcinomas, including bladder, penile, renal pelvis, ureter and transitional cell cancers. With the approval of pembrolizumab and atezolizumab in the relapsed setting following cisplatin therapy, much of the focus has now turned to earlier stage disease.

In our latest Preview, we explore some of the key combinations and look at whether or not they are more promising in terms of outcomes than the monotherapy readouts we have seen to date.  There’s a lot to cover and digest…

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Well, the ASCO abstract drop has certainly brought with it some good, bad, and even confusing data to explore this year, perhaps not helped by some of the weird assumptions and misconceptions being bandied around.

In our latest preview, we take another dozen or so key topics and explore what we know and don’t know in the context of the broader landscape. We also address some of the inaccuracies out there for the unwary.

There’s a lot to learn here and the devil, as always, is in the details.

“There’s just a song in all the trouble and the strife
You do the walk, yeah, you do the walk of life
You do the walk of life.”

So grab a cup of coffee and take a walk through the minefield of initial data with us… after all, not all of it is in dire straits 😉

To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!